Understanding the biological function of specific antibodies against human immunodeficiency virus (HIV) is important for the development of a vaccine. One of the potentially important mechanisms of protection against viral spread is antibody-dependent cellular cytotoxicity (ADCC) (12) . In this reaction, HIV-specific antibodies bind to HIV antigens on the surface of infected cells, which are then killed by Fc receptor-positive effector cells. It has been shown that ADCC to HIV-infected cells is mediated by human immunoglobulin Gl (IgGl) (13) and also that HIV envelope glycoprotein constitutes a target for this reaction (12, 15) .
HIV type 1 (HIV-1)-specific neutralizing antibodies that are able to inhibit viral infection in vitro have been reported (24, 28) , although the protective role of these antibodies against HIV infection in humans is controversial. Several authors have reported that HIV-1-neutralizing antibodies can be produced against various regions of gpl20 (7, 11, 16, 19, 21) , gp4l (9) , and p17 (20) . One major site inducing neutralizing antibodies has been described as a hypervariable loop of gpl20 (4, 25) . Even though several neutralizing monoclonal antibodies (MAbs) (16, 26) have been produced, no MAb mediating ADCC was previously described.
In this report, we present an MAb which mediates both ADCC and neutralization. The region of gpl20 to which it is directed was identified by peptide mapping.
The gpl20 used as an immunogen was prepared from culture fluid of HIV (27) , and immunofluorescence.
The ADCC was determined as described previously (12, 14 One of the MAbs, P4/D10, was able to mediate high HIV-specific ADCC (Fig. 1) . This ADCC activity could also be shown with human HIV antibody-positive sera but not with the other MAbs F58/H3 and T1.1 or with human HIV-seronegative sera. Nor was the reactivity seen when P4/D10 was tested against uninfected target cells.
Of the five MAbs with similar epitopic reactivity and the ability to mediate virus neutralization, two are presented in Table 1 . In addition, an MAb with a different epitopic reactivity to the N-terminal end of gpl20 is presented as a control. The neutralizing capacities of P4/D10 and F58/H3 [D, P4/D1O; *, F58/H3; *, positive human sera; *, negative human sera; *, Ly.
were high (Table 1) . Both neutralized human T-cell lymphotropic virus type IIIB infection of peripheral blood lymphocytes and the CD4+ cell line HUT-78. MAb F58/H3, which was unable to mediate ADCC, had a high neutralizing titer, while the ADCC-positive P4/D1O MAb had a less efficient but still significant neutralizing capacity. Neither of the MAbs showed any toxic effects in the assays. In ELISA, P4/D1O and F58/H3 showed a strong reactivity with pBl. Fine mapping of the epitopes of these two MAbs was performed with synthetic peptides representing the whole pBl sequence (Fig. 2a and b) . A specific reactivity of both P4/D1O and F58/H3 was found only to peptides C53 and C54, which represent aa 304 to 323.
In addition, specific peptide blocking was performed ( Fig.  2c and d) . A complete inhibition of reactivity of both MAbs was seen with peptide C53, while C54 only partly inhibited the MAb binding to pBl.
Thus, an MAb that mediates HIV-specific ADCC and neutralization was identified, and the specificity appeared to be directed toward an epitope located on two overlapping peptides, of which the common sequence is IQRGPGRAF (Table 1) . GPGRA is a conserved sequence within a variable putative loop region which has been found to induce neutralizing antibodies in animals (25) . No clear correlation has previously been demonstrated between neutralization and ADCC, but it is reasonable to suggest that there are several ADCC and neutralizing epitopes. However, only one ADCC-mediating epitope at the very C-terminal part of gpl20 has been suggested previously (2) . A correlation was found between high ADCC titers and reactivity to aa 304 to 313 in a few human sera (unpublished data).
The importance of the isotype of murine MAbs mediating ADCC with human effector cells varies in different studies. IgG2a and IgG3 were the predominant isotypes for ADCC (1, 6, 10) , but efficient ADCC mediated by IgGl and IgG2b has also been reported (5, 18, 22) . The two MAbs described here reacted with the same peptides but differed in ADCC and neutralizing activity. The region which induces neutralizing antibodies (aa 296 to 331) might include a large proportion of the protein, while the epitope inducing ADCCmediating antibodies appears to be a limited sequence within this neutralization-inducing region. 
